A former ANZ trader who alleges he was sacked for complaining about the bank’s manipulation of the bank bill swap rate has lost his bid to view lawyers’ notes taken during meetings over ASIC’s investigation into the bank’s conduct.
The Port of Newcastle has largely won its High Court fight with mining giant Glencore over access fees and will now be able to set a higher price for use of the port’s facilities.
Liberty Mutual Insurance does not have to indemnify dam operator Sunwater for its share of a $440 million settlement of the Queensland floods class action, the NSW Supreme Court has found.
Former Commonwealth Bank subsidiary Avanteos Investments Limited pleaded guilty on Wednesday to charging up to $700,000 in fees to hundreds of deceased superannuation fund members.
Group members in a class action over Bayer’s Essure contraceptives had “a ticking time bomb” in their bodies after being implanted with the devices, and all were at risk of developing injuries, a court has heard.
Union members who allegedly urged former Qantas workers to give misleading information to the Federal Court via a survey in a lawsuit brought on behalf of 2,000 stood-down ground staff may be called to explain themselves after a judge expressed concern over their conduct.
Mercedes-Benz has responded to a $650 million lawsuit by Australian dealers over its decision to move to a fixed-price agency model, saying it had a “legitimate commercial interest” in making the change and denying that dealer agreements were “perpetual” in their terms.
A judge was “mistaken” to find that AFT Pharmaceuticals’ ads for its painkiller Maxigesic were misleading, with the Full Federal Court ruling there was an adequate scientific foundation for the ads’ claims that the drug provided faster, better pain relief than paracetamol and ibuprofen alone.
The Finance Sector Union is preparing a lawsuit against the National Australia Bank, claiming the bank has pressured its employees to work “unreasonable” hours and underpaid its staff.
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.